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Background: By definition, a generic product is considered interchangeable with the innovator brand product.
Controversy exists about interchangeability, and attention is predominantly directed to contaminants. In particular
for chronic, degenerative conditions such as in Parkinson’s disease (PD) generic substitution remains debated
among physicians, patients and pharmacists. The objective of this study was to compare the pharmaceutical quality
of seven generic levodopa/benserazide hydrochloride combination products marketed in Germany with the original
product (MadoparW / ProlopaW 125, Roche, Switzerland) in order to evaluate the potential impact of MadoparW
generics versus branded products for PD patients and clinicians.
Methods: MadoparW / ProlopaW 125 tablets and capsules were used as reference material. The generic products
tested (all 100 mg/25 mg formulations) included four tablet and three capsule formulations. Colour, appearance of
powder (capsules), disintegration and dissolution, mass of tablets and fill mass of capsules, content, identity and
amounts of impurities were assessed along with standard physical and chemical laboratory tests developed and
routinely practiced at Roche facilities. Results were compared to the original “shelf-life” specifications in use by Roche.
Results: Each of the seven generic products had one or two parameters outside the specifications. Deviations for the
active ingredients ranged from +8.4% (benserazide) to −7.6% (levodopa) in two tablet formulations. Degradation
products were measured in marked excess (+26.5%) in one capsule formulation. Disintegration time and dissolution for
levodopa and benserazide hydrochloride at 30 min were within specifications for all seven generic samples analysed,
however with some outliers.
Conclusions: Deviations for the active ingredients may go unnoticed by a new user of the generic product, but may
entail clinical consequences when switching from original to generic during a long-term therapy. Degradation products
may pose a safety concern. Our results should prompt caution when prescribing a generic of MadoparW/ProlopaW, and
also invite to further investigations in view of a more comprehensive approach, both pharmaceutical and clinical.
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Parkinson’s disease (PD) is a progressive neurodegenerative
disorder affecting primarily dopaminergic neuronal sys-
tems. Typical manifestations include motor symptoms
(bradykinesia, rigidity, tremor, gait and postural instability)
and non-motor symptoms including cognitive and emo-
tional dysfunction [1-3]. Levodopa or L-dopa is a naturally* Correspondence: isabelle.arnet@unibas.ch
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reproduction in any medium, provided the oroccurring amino acid (L-3,4-dihydroxyphenylalanine). It
is a prodrug and the precursor of dopamine (DA), a
neurotransmitter that is severely reduced in PD due to
degeneration of neuronal cells [2,3]. Levodopa has been
the standard medical therapy for PD since its discovery
approximately 40 years ago [4] and is recognized as a
classic example of a brain neurotransmitter substitution
therapy. When given systemically, levodopa crosses the
blood–brain barrier and is converted to DA by L-dopa
decarboxylase (DDC) [5]. When administered orally, a
high pre-systemic conversion to DA occurs in the gut byLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cing the systemic available dose of levodopa to 30%
[6,7]. Levodopa is thus coadministered in a 4/1 ratio
with an AADC inhibitor such as benserazide hydrochlor-
ide. This combination can triple the oral bioavailability
of levodopa, and markedly reduces both the required
levodopa therapeutic dose and the severity of dopamine-
mediated gastrointestinal and cardiovascular side-effects
[8]. Levodopa has a short half-life of 1.5 h, even when
coadministered with an AADC inhibitor [9]. When ad-
ministered with benserazide hydrochloride, the initial
dose is 100 mg to 200 mg levodopa daily given as levo-
dopa 50 mg/benserazide 25 mg up to 2 to 4 times a
day. Treatment may start at levodopa 300 mg daily in
advanced disease. The recommended maximum main-
tenance dose is 800 mg levodopa daily in multiple di-
vided doses [9,10].
Levodopa is a white or almost white crystalline powder
which darkens on exposure to air and light [10]. It is
odourless, almost tasteless, slightly soluble in water and
soluble in aqueous solutions of mineral acids and alkali
carbonates [10]. Levodopa is purchased on the pharma-
ceutical market. Benserazide hydrochloride is a white or
almost white crystalline powder, slightly soluble in etha-
nol, and soluble in water. Benserazide hydrochloride
decomposes slowly in aqueous solution. It is synthetic-
ally produced by Roche.
MadoparW/ProlopaW 125 mg (levodopa 100 mg +
benserazide hydrochloride 25 mg) exists as scored tab-
lets and capsules for Parkinson’s disease [9].
By definition, a generic product is considered inter-
changeable with the innovator brand product and
needs to demonstrate the same qualitative and quanti-
tative composition in active substances, the same
pharmaceutical form and bioequivalence with the ref-
erence product after a single dose [11]. The different
salts, esters, complexes or derivatives of an active sub-
stance are considered to be the same active substance,
and thus different excipients, colour agents, flavours
and preservatives are allowed. Generics may also dif-
fer in characteristics such as shape, size, colour, scor-
ing configuration, and release mechanisms [12-16].
Controversy exists about interchangeability, mainly
because of the questionable validity of the current cri-
teria the evaluation is performed in a small, young
and healthy population; no clinical efficacy data are
required; short term study [17]. Thus, therapeutic
equivalence is not necessarily guaranteed. However,
attention is predominantly directed to contaminants
that could cause adverse clinical events and ultimately
fatal issues [5-7]. In clinical settings, health profes-
sionals are aware that patient response and suscepti-
bility to levodopa vary widely, especially in advanced
PD, and that levodopa blood levels correlate with theemergence of many symptoms, including motor mani-
festations like dyskinesia and “off” periods. Thus, even
small variations in levodopa availability and conse-
quently subtle fluctuations in levodopa blood levels
can trigger motor complications. Since generic formu-
lations differ from the branded product mainly in
their excipients, which may affect absorption and bio-
availability [15], simple bioequivalence cannot suffice
to ensure comparable clinical efficacy and safety, es-
pecially in PD.
Roche’s standard operating procedures (SOPs) de-
scribe the qualitative and quantitative pharmaceutical
tests for physical and chemical purity of the substance.
They were accepted by regulatory authorities as part
of the MadoparW registration documentation and form
the basis of MapoparW/ProlopaW specifications in the
United States, European and British Pharmacopoeias.
The current investigation compares the pharmaceutical
quality of seven generic products with the specifica-
tions of the original MadoparW and raises questions
about safety and interchangeability.
Methods
Samples of generic levodopa/benserazide hydrochloride
products, all 100 mg/25 mg formulations, were purchased
in 2011 as commercial goods in a community pharmacy in
Germany and tested within their expiry dates.
Pharmaceutical quality tests
The tests were colour (tablets and capsules), colour and
appearance of powder (capsules), mass of tablets and fill
mass of capsules, disintegration and dissolution, content
of active pharmaceutical ingredient (API), and the iden-
tity and amounts of impurities.
Colour
Tablet colour was assessed visually according to the
standards described in the “Munsell Book of Color”
(1996). Capsule colour was assessed by comparison to
reference capsules. MadoparW specifications for colour are
pale red for tablets and flesh-coloured opaque for the cap-
sule body and powder-blue opaque for the capsule cap.
Mass of tablets
Twenty tablets were weighed and average mass was
calculated. MadoparW specifications for average mass of
tablets are 267–283 mg (275 mg ± 3%).
Fill mass of capsules
Twenty capsules were weighed, emptied, and the
empty capsules weighed; the average weight of the capsule
fill mass was derived from the difference. MadoparW
specifications for capsule fill mass are 142.5-157.5 mg
(150 mg ± 5%).
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Tablets and capsules were tested according to Ph. Eur. /
USP (tablets: apparatus A without discs using water at
37°C; capsules: apparatus A using discs and 0.1 M HCl
at 37°C). MadoparW specifications for disintegration time
are not more than 15 min for tablets and not more than
30 min for capsules.
Dissolution
Dissolution was tested using the Ph. Eur. rotating basket
apparatus and 0.1 N HCl at 37°C as the dissolution
medium. Samples were measured by UV-HPLC at
220 nm. MadoparW shelf-life specifications for dissol-
ution after 30 min are at least 75% for tablets and at
least 80% for capsules.
Content of levodopa, benserazide hydrochloride, related
substances and impurities
MadoparW specifications for content of active substances
are levodopa 95.0-105.0 mg (100 mg ± 5%) and benserazide
hydrochloride 27.1-29.9 mg (28.5 mg ± 5%) per unit. The
content of active substances and degradation products
was determined using HPLC. Benserazide is degradated
by hydrolysis to Ro 04–1419, which can bind one mol-
ecule of benserazide to the dimer Ro 08–1580. The
specifications for content of specific degradation prod-
ucts of benserazide hydrochloride are limited to 3.49%Table 1 Physical characteristics of Madopar®/Prolopa® and se
Brand name Manufacturer Colour
Tablets
Madopar Roche Pharmaceuticals Pale red
Levodopa/ Benserazid beta Betapharm Arzneimittel GmbH Pale red, spec
Levodopa/ Benserazid-CT CT Arzneimittel GmbH Pale red, spec
dopadura B MYLAN dura Pale red, spec
Levodopa/ Benserazid
ratiopharm
ratiopharm GmbH Pale red, stron
Capsules
Madopar Roche Pharmaceuticals Body: flesh-co
Cap: powder-
Levopar HEXAL AG Body: flesh-co
Cap: powder-
Levodopa comp. B STADA STADApharm GmbH Body: flesh-co
Cap: powder-
Levobens-Teva TEVA GmbH Body: midnig
Cap: fluoresce(tablets) and 0.49% (capsules). The maximum permissible
amount of other impurities is set at 1.04% (tablets) and
0.54% (capsules). The specifications for other impurities
are no more than 0.54% (tablets) and 0.24% (capsules)
for any individual impurity.
Results
Analysis was performed according to the standard phys-
ical and chemical laboratory tests developed and rou-
tinely practiced at Roche facilities.
Physical characteristics
The physical characteristics of the tested products are
shown in Table 1. None of the generic tablets was cross-
scored on both sides like the original product, but all
had either a single break bar on both sides (Betapharm)
or on one side only. The colours of all generic products
were similar to MadoparW/ProlopaW except for one cap-
sule formulation (Teva).
Mass, fill mass, disintegration time and dissolution rate
Mass exceeded the upper limits of the specifications in
five of the seven generic products (Table 2), and by
almost 200% for all three capsule formulations. Disinte-
gration times (min - max: tablets 4.30 - 6.30 min;
capsules 5.40 -16.10 min) were within specification. Dissol-
ution values after 30 min complied with the specifications,ven generic products
Appearance
Above: cross-scored
Below: cross-scored
kled Above: score line
Below: score line
kled Above: score line
Below: none
kled Above: score line
Below: none
gly speckled Above: score line
Below: none
Appearance of the content Colour of the content
loured, opaque Fine granular powder Light beige
blue, opaque
loured, opaque Fine granular powder Brown
blue, opaque
loured, opaque Fine granular powder Almost white
blue, opaque
ht blue, opaque Fine granular powder Almost white
nt-pink, opaque
Table 2 Mass, content of active ingredients, and dissolution time of seven generic products compared to Madopar®/
Prolopa® specifications
Brand name Mass (mg) Levodopa (mg) Benserazide hydrochloride (mg) Dissolution after 30 min
Tablet specifications 267.0-283.0 95.0-105.0 27.1-29.9 >75%/ >75%
Levodopa/ Benserazid beta 265 92.4* 30.9* 99% / 99%
Levodopa/ Benserazid-CT 284* 98.2 27.8 101% / 97%
dopadura B 283 94.4* 26.9* 100% / 97%
Levodopa/ Benserazide ratiopharm 284* 95.5 28.8 101% / 98%
Capsule specifications Fill mass (mg) 142.5-157.5 95.0-105.0 27.1-29.9 >80%/ >80%
Levopar 298.6* 98.3 27.5 80% / 84%
Levodopa comp. B STADA 299.0* 98.7 27.6 100% / 96%
Levobens-Teva 222.3* 99.5 28.3 89% / 86%
* Values marked with an asterisk indicate deviations from Roche specifications.
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(Levobens-Teva 16%, 25%; Levopar 68%, 49%, 72% 78%),
indicating large variations in dissolution properties for sin-
gle capsules.
Content of active substances, degradation products, and
impurities
Content requirements for the active substances were un-
met in two of the four tablet formulations, with content
of levodopa below the limits, and content of benserazide
hydrochloride below and above the limits (Table 2). All
products contained impurities, exceeding the limits by
79% in one generic product (Table 3).
Discussion
Comparison of the pharmaceutical quality of MadoparW/
ProlopaW with seven generic products showed that at
least one of the tested parameters fell outside Roche shelf-
life specifications in all products tested and identified two
areas of concern: Content of active substances and impur-
ities. Since even small variations of levodopa availability
and consequently subtle fluctuations in levodopa bloodTable 3 Identity and amounts of related substances and impu
Prolopa® specifications
Degradation product Ro 04-1419 Ro 08-1580
Tablets Upper limits (%) 1.54 2.49
Levodopa/ Benserazid beta 0.35 0.47
Levodopa/ Benserazid-CT 0.28 0.48
Levodopa/ Benserazide ratiopharm 0.25 0.37
dopadura B 0.26 0.34
Capsules Upper limits (%) 0.54 0.54
Levopar 0.12 0.34
Levodopa comp. B STADA 0.16 0.32
Levobens-Teva 0.36 0.25
*Values marked with an asterisk indicate deviations from Roche specifications.levels can trigger motor complications, the observed out-
of-specification values could suffice to unbalance symp-
tom management, especially in stabilized patients. In
switching to a new formulation, patients may face weeks of
complex retitration and further visits to their neurologists.
In 2010–11 the worldwide shortage of branded Sinemet
(carbidopa-levodopa), followed by shortage of its generic
formulation (all formulations and all dosages), revealed the
distress of the Parkinson community through the testi-
mony of thousands of patients forced to switch to generics
[18]. Patients uniformly reported a negative experience
and several clinical issues, e.g. slower onset of effect,
faster waning of effect, dose adjustment to compensate
for the decreased medication effect, symptom exacerbation
(e.g. dyskinesia), and side effects such as poorer sleep qual-
ity and increased impulsivity. No patient reported a prefer-
ence for the generic version. Replacement medication was
perceived as less effective, probably due to patients receiv-
ing differing generics at each renewal, thus getting fluctua-
tions in blood levels with every new product.
The development of a branded formulation requires
the assessment of pharmacokinetic parameters in healthyrities in seven generic products compared to Madopar®/
Ro 04-1419 + Ro 08-1580 Others each Others total
3.49 0.54 1.04
0.83 0.19, 0.09 0.28
0.75 0.09, 0.08 0.17
0.62 0.16, 0.05 0.21
0.60 0.12 0.12
0.49 0.24 0.54
0.46 0.10 0.10
0.49 0.11, 0.11 0.11
0.62* 0.10, 0.12, 0.10 0.33
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safety and tolerability in the target patient population.
Market authorisation for generic equivalents, however,
requires only the documentation of bioequivalence with
branded counterparts in healthy subjects, using one lot
of branded product, and without accounting for country
to country differences [19,20]. Some small studies [21,22]
suggested that the generic formulation of carbidopa-
levodopa given in a single dose to PD patients was bio-
equivalent to brand Sinemet. However, the same au-
thors report clinical worsening with marked motor
fluctuations in a long-term open-label study following
conversion to generic carbidopa-levodopa [21]. Ap-
proval by the authorities is based on the assumption
that demonstrating bioequivalence in pharmacokinetic
studies in healthy volunteers suffices to demonstrate
similar tolerability and efficacy in patients. Differences
in the excipients used for generic formulations and the
presence of impurities which may affect both the ab-
sorption and bioavailability of active ingredients in
patients create a potential risk of “relative therapeutic
in-equivalence” [15]. Furthermore, the intra-individual
peculiarity of PD patients, such as slow absorption of
the first orally administered dose of medication in the
morning due to low gastric motility [23] makes the
variability of blood concentrations from generic drugs
unpredictable. Furthermore, PD patients often use mul-
tiple drugs e.g., dopamine agonists, monoamine oxydase
inhibitors, anticholinergics, and psychotropics. Since is-
sues regarding drug-drug interactions are not addressed
by bioequivalence studies, potential risks cannot be
excluded [1,23]. Unpredictable blood concentrations
also expose patients to a higher risk of concentration-
dependent drug-drug interactions. In addition, un-
known excipients and impurities may trigger allergic
reactions or even intolerance [24,25]. Score lines are a
further area of concern. MadoparW/ProlopaW is cross-
scored for easy splitting, since many patients commonly
split their tablets to adjust their doses. Easy splitting of
the medication for optimal individual dosing is a critical
patient-care requirement. Without score lines, or with
only one score line on one side, as in three of the test
generic tablets, tablet splitting usually requires the use
of a sharp blade, which is a clear safety issue for a per-
son with PD.
Conclusions
In conclusion, these results demonstrate areas of con-
cern in the pharmaceutical quality of generic products,
such as the content of active substances, and the com-
position and amount of impurities. The potential risks
of “relative therapeutic in-equivalence,” drug-drug inter-
actions, and allergic reactions or intolerance should
prompt caution when prescribing a generic product ofMadoparW/ProlopaW, in particular in highly susceptible PD
patients with co-morbidities requiring comedication. We
recommend considering the substitution of Parkinson’s
medication as a change in medication, requiring guidance
and supervision by the patient’s physician. Any generic can
be used to initiate first treatment. It will be effective and
less expensive than the branded product, but will need a
similar process of titration until symptom control is
achieved. The challenge for patient, prescribing physician
and pharmacist will be to ensure that the same generic for-
mulation is dispensed at each refill. Switching back and
forth between brand and generic, or even between ge-
nerics, is a recipe for problems that may cancel out the sav-
ings achieved with the cheaper drug. Ultimately, it is the
responsibility of the physician-patient-pharmacist triad to
arrive at the best choice for the best patient outcome.
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